ArticleAnnals of surgical oncology2025
Disparities in Extended Venous Thromboembolism Prophylaxis After Pancreatic Cancer Surgery.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Challenges in Venous Thromboembolism Risk Stratification After Pancreatic and Liver Cancer Surgery Using Claims Data.Journal of surgical oncology · 2026Article
- Poverty and Mortality Risk in Patients With Colorectal Cancer.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCurrent guidelines recommend extended venous thromboembolism (VTE) prophylaxis for 4 weeks following pancreas surgery for cancer; however, adherence to these guidelines is low.
methodsThis is a retrospective analysis of the 2007-2020 SEER-Medicare dataset for patients with primary pancreas cancer undergoing pancreas surgery. The primary outcome was the filling of a prescription for extended VTE prophylaxis within 5 days of discharge. The independent variables included patient demographics, social determinants of health, comorbidities, and cancer and treatment characteristics. We used multivariable logistic regression to identify variables independently associated with extended VTE prophylaxis.
resultsWe identified 4,827 eligible operations (72% pancreatoduodenectomies). The median age was 73 years, and 54.7% were female. Extended VTE prophylaxis prescriptions were filled for 469 patients (9.7%), primarily with enoxaparin (96.2% of prescriptions). Filling of extended VTE prescriptions increased over time (0.4% in 2008 to 23.1% in 2019). After risk adjustment, factors independently associated with receipt of extended VTE prophylaxis included younger age (odds ratio [OR] 1.02, 95% confidence intervals [CI] 1.01-1.04), white race (OR 2.2 [1.5-3.4]), rurality (nonmetropolitan area vs. metropolitan >1 million population, OR 1.6 [1.2-2.1]), pancreatoduodenectomy (vs. other pancreas surgery, OR 1.4 [1.1-1.8]), higher pancreatectomy hospital volume (4th vs. 1st quartile, OR 2.3 [1.5-3.5]), surgical oncologist provider specialty (OR 2.3 [1.9-2.8]), and surgery period (2016-2019 vs. 2008-2011, OR 5.9 [4.2-8.6]).
conclusionsPrescription of extended VTE prophylaxis after pancreas cancer surgery has been modest but increasing. Disparities in the receipt of extended VTE prophylaxis are multifactorial, mostly stemming from demographic and healthcare-related factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.